AbbVie prices Rinvoq close to Humira after arthritis approval - pharmaphorum

AbbVie prices Rinvoq close to Humira after arthritis approval  pharmaphorum

AbbVie claimed FDA approval for its JAK inhibitor Rinvoq (upadacitinib) for rheumatoid arthritis on Friday, setting its price just a little below that of its antibody ...



Comments

Popular posts from this blog

Fibromyalgia — Latest Stories — Pain News Network

Chronic Lyme arthritis: A mystery solved?

Epstein-Barr virus and autoimmune diseases